Business Standard
Thursday, May 31, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
  Home  ||||||||| 
 BS Headlines | News Now | BS Weekend | The strategist | smartinvestor.in | E-Paper | SME | Power | Budget 2012 | BS 1000 | PM in Myanmar | Rajat Gupta
Home > Live Markets | Commodities
 

Ranbaxy gains WHO pre-qualification for Indinavir - 400mg ARV capsules
Announcement / Corporate Nov 12, 2009, 20:05 IST

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the World Health Organisation, Geneva (WHO), has included the Company’s Indinavir (as sulfate) - 400mg Anti Retroviral (ARV) Capsule, in its pre-qualification list.

With this new addition, Ranbaxy now has a total of 19 ARVs on the WHO pre-qualification list.

Commenting on the WHO listing, Ranbaxy's CEO &MD, Mr. Atul Sobti said, "Ranbaxy remains committed to provide high quality affordable generic ARV medicines and will continue to dedicate itself in fighting the worldwide struggle against HIV/AIDS."

Ranbaxy's ARVs, including the recently approved WHO pre-qualified products, are manufactured at the Company's state-of-the-art manufacturing facilities.

Since 2001, Ranbaxy has been providing high quality ARV medicines, at affordable prices , in over 70 markets worldwide, thereby facilitating access to patients afflicted by HIV/AIDS who might not otherwise have been able to gain access to this therapy. The Company's ARVs have been used as mainstays in various large treatment programs, both National and NGO/Institutional with good results. ARV medicine produced by Ranbaxy are used by over 400000 patients worldwide , in various developing and underdeveloped countries.

Ranbaxy is committed to supporting the global fight against HIV/AIDS through high quality, affordable medicines.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 10 countries.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets languish as heavyweights drag
- Mentha oil rebounds as demand picks up
- Bandh evokes good response in UP
- Speciality Restaurants hits upper circuit on stake buys by Reliance MF
- Silver futures down 0.5% on global cues, weak spot demand
  Read Business news in 
- India's no. 1 Property Site. Click here to know more
- "Discover The Power of One"
- Help a Child Achieve her. Click to know more
- Watch The Film Here. Click here to know more..
- Learn How One City is Running on FOOD SCRAPS.
- 1 billion in saving for Unilever without any tangles.
- Helping doctors detect diseases earlier, saving costs & extending lives.
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
- 2 Lac Apartments, 1 Lac House / Plots. Click here
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- NDA-led bandh turns violent in Bangalore
- Investors wary as Flipkart shows growth pangs
- Army chief slams BEML on Tatra, awards it Rs 1,500-cr deal
- Wealthy clients turned tables on UBS and staff?
- Kingfisher Airlines Q4 loss more than trebles
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
  Hot Searches  
 
Apalya |  Air India |  GAAR |  Agni  |  Solar eclipse |  Satyamev Jayate |  SRK |  Aamir Khan |  IPL |  Ertiga |  Sarfaesi Act |  Vodafone |  JP Morgan |  Transfer pricing |  Rupee |  Kingfisher Airlines |  Silver |  Provident Fund |  income tax refund |  iPhone |  Reliance Industries |  SEBI |  BSNL |  BSE |  NSE |  Mukesh Ambani |  Anil Ambani |  Infosys |  Pranab Mukherjee |  Sonia Gandhi |  Rahul Gandhi |  New Pension Scheme |  Reliance |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  B-School |  Sensex |  Tax calculator |  Home Loan |  Personal Finance |  inflation |  oil prices |  Barack Obama |   
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us